Recurrent Thyroid Cancer Diagnosis. ROC Study of the Effect of a High-Resolution Head and Neck 18F-FDG PET/CT Scan.

Academic Radiology

Volumn 21, Issue 1, 2014, Pages 58-63

  Chatziioannou, Sofia N ^a,b   Georgakopoulos, Alexandros T ^a   Pianou, Nikoletta K ^a   Kafiri, Georgia Th ^c   Pavlou, Spyros N ^c   Kallergi, Maria ^d  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c Endocrine Unit   (Greece)

^d UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

FDG; PET CT, ROC; Positron emission tomography; Thyroid cancer

Indexed keywords

FLUORINE 18;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MALE; NECK; PRIORITY JOURNAL; PROSPECTIVE STUDY; THYROID CANCER; WHOLE BODY SCINTISCANNING;

FDG; PET/CT, ROC; POSITRON EMISSION TOMOGRAPHY; THYROID CANCER;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84890238742     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2013.09.017     Document Type: Article

References (16)

1. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy. InVivo 2008, 22:109-114.
2. Lind P., Kohlfürst S. Respective roles of thyroglobulin, radioiodine imaging and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 2006, 36:194-205.
3. Abraham T., Schöder H. Thyroid cancer-indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 2011, 41:121-138.
4. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imaging 2007, 34:487-495.
5. 18F FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma. Clin Nucl Med 2008, 33(7):464-468.
6. Dorfman D.D., Berbaum K.S., Lenth R.V., et al. Monte Carlo validation of a multireader method for receiver operating characteristic discrete rating data: Factorial experimental design. AcadRadiol 1998, 5:591-602.
7. Hillis S.L., Berbaum K.S. Power estimation for the Dorfman-Berbaum-Metz method. Acad Radiol 2004, 11:1260-1273.
8. Hillis S.L., Obuchowski N.A., Schartz K.M., et al. A comparison of the Dorfman-Berbaum-Metz and Obuchowski-Rockette methods for receiver operating characteristic (ROC) data. Stat Med 2005, 24:1579-1607.
9. Hillis S.L., Berbaum K.S. Monte Carlo validation of the Dorfman-Berbaum-Metz method using normalized pseudovalues and less data-based model simplification. Acad Radiol 2005, 12:1534-1541.
10. Hillis S.L. A comparison of denominator degrees of freedom for multiple observer ROC analysis. Stat Med 2007, 26:596-619.
11. Dorfman D.D., Berbaum K.S., Metz C.E. Receiver operating characteristic rating analysis. Generalization to the population of readers and patients with the jackknife method. Invest Radiol 1992, 27:723-731.
12. Hillis S.L., Berbaum K.S., Metz C.E. Recent developments in the Dorfman-Berbaum-Metz procedure for multireader ROC study analysis. Acad Radiol 2008, 15:647-661.
13. Pesce L.L., Metz C.E. Reliable and computationally efficient maximum-likelihood estimation of "proper" binormal ROC curves. Acad Radiol 2007, 14:814-829.
14. Stokkel M.M., Duchateau C.J., Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006, 50:78-87.
15. Yeo J.S., Chunk J.K., So Y., et al. F-18 fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001, 23:94-103.
16. Hustinx R., Smith R.J., Benard F., et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999, 26:1345-1348.